Skip to NavigationSkip to content

Vitae Pharmaceuticals

Vitae Pharma soars on positive mid-stage trial results for psoriasis drug

Shares in Vitae Pharmaceuticals (Nasdaq: VTAE) nearly doubled in pre-market trading Thursday after the company reported mid-stage trials of its psoriasis drug significantly reduced the skin condition.

The company said, patients taking 350 mg dose of drug candidate VTP-43742, demonstrated a 24% reduction in the psoriasis area severity index than the placebo, while for patients taking the 700 mg dose witnessed a 30% decrease.

Dr Karen Bernstein joins Ovid and Vitae boards

Published on: 01/10/15

Ovid Therapeutics has announced the appointment of Karen Bernstein to the company's Board of Directors.

Dr Bernstein says: “I have had the great pleasure to know the members of Ovid’s team over many years, and it is very exciting to see this group come together in forming a new company that I believe will make a major difference for patients with rare and orphan diseases of the brain. Recent scientific insights in CNS diseases open new avenues for the development of important new drugs. Ovid is uniquely suited to become a major player in this area.

Boehringer and Vitae Pharma drug fails in mid-stage trial

BI building
Image: Boehringer Ingelheim GmbH

A pipeline diabetes drug co-developed by Vitae Pharma and German giants Boehringer Ingelheim has failed to show benefits in a Phase II trial.

Pennsylvania-based Vitae Pharma said the proof-of-concept study, which looked at the investigational diabetes treatment BI187004/VTP-34072 in combination with metformin, failed to reach its primary endpoint – reducing fasting blood sugar levels.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches